

Adriaan Kooy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6631874/publications.pdf>

Version: 2024-02-01

16
papers

1,342
citations

1040056

9
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

1854
citing authors

#	ARTICLE	IF	CITATIONS
1	Pregnancy Outcomes: Effects of Metformin (POEM) study: a protocol for a long-term, multicentre, open-label, randomised controlled trial in gestational diabetes mellitus. <i>BMJ Open</i> , 2022, 12, e056282.	1.9	3
2	Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia. <i>Pharmaceuticals</i> , 2022, 15, 312.	3.8	20
3	Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial. <i>Cardiovascular Diabetology</i> , 2022, 21, 49.	6.8	1
4	Effect of metformin on arginine and dimethylarginines in patients with advanced type 2 diabetes: A post hoc analysis of a randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1983-1988.	4.4	2
5	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from <sc>DECLARE-TIMI</sc> 58. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 29-38.	4.4	28
6	Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial. <i>PLoS ONE</i> , 2021, 16, e0247939.	2.5	3
7	The Role of Self-Regulation in the Effect of Self-Tracking of Physical Activity and Weight on BMI. <i>Journal of Technology in Behavioral Science</i> , 2020, 5, 206-214.	2.3	1
8	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	11.4	166
9	How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 968-974.	4.4	66
10	Long-term treatment with metformin in type 2 diabetes and vitamin <sc>D</sc> levels: <sc>A</sc> <i>post-hoc</i> analysis of a randomized placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1951-1956.	4.4	14
11	Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 219-223.	4.4	8
12	Metformin and β -cell function in insulin-treated patients with type 2 diabetes: A randomized placebo-controlled 4.3-year trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 730-733.	4.4	5
13	Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3 year trial. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 171-178.	2.3	53
14	Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. <i>BMJ: British Medical Journal</i> , 2010, 340, c2181-c2181.	2.3	433
15	Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2009, 169, 616.	3.8	354
16	Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 2133-2140.	8.6	185